# A Chemical Linker for Attaching Drugs to Antibodies

> This patent describes specific chemical linkers that can securely attach powerful drug molecules to antibodies, creating targeted therapies like those used in cancer treatment.

- **Patent:** US 10772965
- **Original title:** Covalent linkers in antibody-drug conjugates and methods of making and using the same
- **Owner:** Rc Biotechnologies
- **Granted:** 2020
- **Status:** Active
- **Times cited:** 1
- **Field:** pharmaceutical, biotech, oncology

## What it does

This patent provides novel chemical compositions for a "linker-active agent." This agent has two main parts: a "linker" and an "active agent." The linker is specifically designed with a structure (Formula I) that can chemically bond, or "covalently couple," to specific chemical groups called "free thiols" found on an antibody. The "active agent" (Q) is then attached to this linker, and it can be a drug, like a "tubulin binder" or "DNA alkylator," or even a "visualization agent." For example, this technology could be used to attach a chemotherapy drug to an antibody that specifically recognizes cancer cells, allowing the drug to be delivered directly to the tumor.

## What it does NOT cover

- Linkers that do not attach to "free thiols" on an antibody, such as those that attach to lysine residues.
- Linkers that do not conform to the specific chemical structure of Formula I as described in claim 1.
- Linkers that use different reactive groups for attachment to the antibody than those listed for R1 and R2 (e.g., maleimide, halogen, alkanal).
- Linker-active agents that are identical to the specific chemical structure explicitly excluded by the provision in claim 1.
- Linkers that are not designed to carry an "active agent" such as a drug, enzyme inhibitor, or visualization agent.

## The clever bit

The clever bit lies in the precise chemical design of the linker (Formula I) and its reactive groups (R1, R2). This specific architecture allows for stable and controlled covalent attachment to an antibody's thiol groups while also providing a way to carry and potentially release a potent active agent, which is critical for the effectiveness and safety of targeted drug delivery.

## Real-world examples

1. Kadcyla (trastuzumab emtansine)
2. Adcetris (brentuximab vedotin)
3. Enhertu (trastuzumab deruxtecan)
4. Trodelvy (sacituzumab govitecan)
5. Padcev (enfortumab vedotin)

## Why it matters

This patent contributes to the field of Antibody-Drug Conjugates (ADCs), which are a rapidly growing class of targeted cancer therapies. By providing specific, stable linker chemistries, it helps ensure that the drug stays attached to the antibody until it reaches the target cells, minimizing damage to healthy tissues. This precision is crucial for developing safer and more effective treatments for diseases like cancer.

## Frequently asked questions

### What does A Chemical Linker for Attaching Drugs to Antibodies cover?

This patent describes specific chemical linkers that can securely attach powerful drug molecules to antibodies, creating targeted therapies like those used in cancer treatment.

### Who owns patent US 10772965?

Rc Biotechnologies owns this patent, granted in 2020.

### When does this patent expire?

This patent is expected to expire on February 14, 2038, when the invention enters the public domain.

### What is patent US 10772965 cited by?

This patent has been cited by 1 later patents that build on its ideas.

### What problem does this patent solve?

This patent contributes to the field of Antibody-Drug Conjugates (ADCs), which are a rapidly growing class of targeted cancer therapies. By providing specific, stable linker chemistries, it helps ensure that the drug stays attached to the antibody until it reaches the target cells, minimizing damage to healthy tissues. This precision is crucial for developing safer and more effective treatments for diseases like cancer.

### What does this patent NOT cover?

Linkers that do not attach to "free thiols" on an antibody, such as those that attach to lysine residues.

**Full plain-English explainer:** https://patentbrief.org/patent/us/10772965/covalent-linkers-in-antibody-drug-conjugates-and-methods-of-making-and-using-the

**Original patent:** https://patents.google.com/patent/US10772965

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [Making Cancer-Fighting Antibody Drugs Safer with Precise Attachment](https://patentbrief.org/patent/us/12121527/anthracycline-based-antibody-drug-conjugates-having-high-in-vivo-tolerability) — This patent describes a specific way to build antibody-drug conjugates (ADCs) for cancer treatment by precisely attaching chemotherapy drugs to antibodies to make them safer inside the body.
- [Making Antibody Drug Conjugate Medicines Consistent Across Batches](https://patentbrief.org/patent/us/20230364252/methods-for-formulating-antibody-drug-conjugate-compositions) — This patent describes methods for precisely controlling the drug amount in antibody drug conjugate (ADC) medicines, ensuring each batch has a consistent strength and effect.
- [Targeted Cancer Drugs Using Antibodies and Polymer Scaffolds](https://patentbrief.org/patent/us/20210301031/napi2b-targeted-antibody-drug-conjugates-and-methods-of-use-thereof) — This patent describes a new way to deliver powerful cancer drugs directly to tumor cells using a specific antibody attached to a special polymer, aiming to reduce side effects.
- [How to Build Smaller, Synthetic Antibody-Like Molecules for Medicine](https://patentbrief.org/patent/us/5455030/immunotheraphy-using-single-chain-polypeptide-binding-molecules) — This patent describes a way to create small, single-chain proteins that mimic the binding power of full-sized antibodies to deliver medicine more effectively.
- [Targeted Platinum Drugs for Cancer Treatment](https://patentbrief.org/patent/us/9884123/ligand-targeted-molecules-and-methods-thereof) — This patent describes a way to deliver platinum-based cancer drugs directly to tumor cells by attaching them to a special 'ligand' molecule that seeks out cancer cell markers.
